Prostate cancer is a type of cancer developed in the prostate gland (in males), and it spreads into other parts of the body particularly the bones and lymph nodes. And prostate cancer diagnostics is the identification/screening process to detect undiagnosed prostate cancer cells in men that show no symptoms/signs. Diagnosis is done by finding out the nature & cause of cancer, understanding the variations occurring in the body cells and determination of the effect to other parts of the body and refer a patient for a subsequent treatment. Prostate cancer diagnostics aids in early treatment of the cancer before it spreads to other parts of the body, provides various treatment measures that can cure and heal a person completely if a person is at an early stage and various other benefits. Some of the simple tools used in prostate cancer diagnosis are: digital rectal examination (DRE) and prostate-specific antigen (PSA) in the blood.
Prostate Cancer Diagnostics Market: Key Players
The research study includes profiles of leading companies operating in the global prostate cancer diagnostics market. Key players profiled in the report include: Abbvie Inc., Dendreon Pharmaceuticals LLC, AstraZeneca, Bayer AG, MDx Health; Myriad Genetics, Inc.; Abbott Laboratories; F. Hoffman-La Roche AG; Siemens Healthineers AG; Johnson & Johnson Services Inc., OPKO Health, Inc.; and Genomic Health.
Drivers for the Global Prostate Cancer Diagnostics Market:
Rising demand of prostate cancer diagnostics for geriatric population as they have high prevalence rate of prostate cancer (about 80% of men who reach 80 years of age are diagnosed with it), prostate cancer is known to be second most common type of cancer in males hence it requires diagnosis & treatment, increasing technological advancements of diagnostics techniques that are safe, genetics can pass on the cancer & hence a person with a family history of cancer can diagnose themselves to prevent any growth of cancer cells at an early stage and cancer is a life taking disease hence the diagnostics plays a major role to detect it and help prevent the growth & save lives. Hence these are the major drivers of the market and are owing to increase the growth and disposable income of the market.
Opportunities for the Global Prostate Cancer Diagnostics Market:
Moreover, AI tools are being used using an MRI to detect cancer cells which provide accurate results, increasing health concerns to avoid cancer, government initiatives to encourage new diagnostics devices & technologies that are safe to the body, increasing medical tourism, increasing number of geriatric population, increasing preference towards serum based testing for detecting prostate cancer and introduction of early prostate cancer recognition tools. Hence these factors are going to provide future opportunities for the market.
Restrains for the Global Prostate Cancer Diagnostics Market:
However, complexities associated with prostate cancer diagnostics, high costs for diagnostic procedures, some diagnostic procedures can cause damage to the surrounding cells and risk of other infections during diagnosis of prostate cancer. Hence these factors are going to majorly hamper the growth of the prostate cancer diagnostics market.
Region Wise, Global Prostate Cancer Diagnostics Market Analysis:
North America held major share in the market due to investment in technology, general economic conditions, high prevalence of the prostrate cancer that require diagnostics, government initiatives to make available early diagnosis, increasing number of hospitals & diagnostic centers, high number of gieratric population and presence of diagnostic manufacturing companies. Besides Europe and Asia-Pacific held a large share in the market.
Covid-19: Impact and Recovery Analysis for Global Prostate Cancer Diagnostics Market:
The world is greatly affected by the uncertain raise of the covid-19 Pandemic among the population. The Corona virus outbreak has disrupted & disturbed every sector of business as well as human activity. In most parts of the world there has been a complete restriction set by governments regarding various activities and in turn this is greatly affecting the financial stability of industries like: prostate cancer diagnostics market globally. Most of the industries and businesses like: Prostate Cancer Diagnostics market is shifting towards manufacturing equipment that can support the covid-19 from increasing and spreading. The prostrate cancer diagnosis market hasn’t faced much of a negative impact as the treatment & diagnosis did not halt due to the rise in corona but on the other hand the diagnostic kits manufacturing centers have been shut due to the lockdown of various governments hence this has negatively impacted the market. The prostrate cancer diagnostics also doesn’t have much of a loss to recover but whatever loss faced due to the shift towards corona patient identification will be overcome by increasing corona diagnosis equipment and providing ultimate sanitization in hospitals or while manufacturing of prostrate cancer diagnostic kits.
Global Prostate Cancer Diagnostics Market: Product analysis
- Preliminary Tests
- PSA Testing
- Digital Rectal Exam
- Biomarker Tests
- Confirmatory Tests
- PCA3 Test
- Trans-rectal Ultrasound
- Biopsy
Global Prostate Cancer Diagnostics Market: Application analysis
- Hospital & Clinics
- Diagnostic Laboratories
- Cancer Research Institutes
- Others
Global Prostate Cancer Diagnostics Market: Region analysis
- North America
- U.S.
- Canada
- Mexico
- Europe
- U.K.
- France
- Germany
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- South Korea
- ASEAN
- India
- Rest of Asia Pacific
- Latin America
- Brazil
- Argentina
- Colombia
- Rest of L.A.
- Middle East and Africa
- Turkey
- GCC
- UAE
- South Africa
- Rest of Middle East
